Head-to-head · WeighScore
CoreAge Rx vs Hers
The verdict
CoreAge Rx takes it — 91.8/100 to 63.9/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoreAge Rx | Hers |
|---|---|---|
| WeighScore | 91.8/100 | 63.9/100 |
| Grade | A− | C |
| Scorecard rank | #1 | #252 |
| Semaglutide | $149/mo | $199/mo (starting dose, compounded) |
| Tirzepatide | $349/mo | $299/mo (starting dose, plus a separate fee, brand-name) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #1 · A−
Strengths
- Flat all-in price with no month-two step-up
- Semaglutide and tirzepatide on one account
- All 50 states, LegitScript-verified
Where it loses points
- Not the cheapest sticker price
- Compounded only
- Pharmacy partner not yet publicly named
Graded #252 · C
Strengths
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.